Scarica l'app Stockscreener
0.4319
5.16%
-0.0235
Dopo l'orario di chiusura:
.43
-0.0019
-0.44%
Precedente Chiudi:
$0.4554
Aprire:
$0.469
Volume 24 ore:
923.43K
Relative Volume:
0.71
Capitalizzazione di mercato:
$42.36M
Reddito:
$190.00K
Utile/perdita netta:
$-70.03M
Rapporto P/E:
-0.5882
EPS:
-0.7343
Flusso di cassa netto:
$-59.30M
1 W Prestazione:
-14.22%
1M Prestazione:
-18.34%
6M Prestazione:
-53.85%
1 anno Prestazione:
-91.76%
Intervallo 1D:
$0.4301
$0.4694
Intervallo di 1 settimana:
$0.4301
$0.51
Portata 52W:
$0.395
$6.50
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.4319 | 44.67M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight - Yahoo Finance
Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program - biospace.com
aTyr Pharma (ATYR) Holds at $0.50 as Mild Buying Interest Supports Biotech Micro-CapThrowback Trade - siam.in
aTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis Study - quiverquant.com
Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis - TradingView
aTyr Pharma Provides Update on Timing of Regulatory - GlobeNewswire
FDA response expected by mid-September for aTyr’s lung disease trial - Stock Titan
aTyr Pharma Inc. (LIFE) Peer Comparison – Compare with Others - Value Research
Corporate Presentation Materials of aTyr Pharma, Inc. dated June 2026SEC.gov - SEC.gov
aTyr Pharma Inc. (LIFE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
aTyr (ATYR) Snapshot: Falls 0.20% to $0.50 on the Day; Immediate View: Price Remains Between $0.47 Support and $0.53 Resistance in the Latest SessionPrice Momentum Stocks - vinanet.vn
FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III - Freedom Broker
aTyr Pharma Company Profile & Introduction - Moomoo
ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesFree Cash Flow Trends - vinanet.vn
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright - MarketBeat
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Why is aTyr Pharma stock gaining today? By Investing.com - Investing.com India
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating - moomoo.com
Why is aTyr Pharma stock gaining today? - Investing.com
Levi & Korsinsky Urges aTyr (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - The National Law Review
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - The National Law Review
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ATyr Pharma Announces Second Quarter 2026 Res - Moomoo
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD - The Manila Times
aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates - scanx.trade
ATYR Looks 13.6% Overvalued on GF Value™ as Cash Supports Develo - GuruFocus
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus - GuruFocus
ATyr Pharma Sees Funding Sufficient Into Late 2028 >ATYR - moomoo.com
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky - The National Law Review
ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - marketscreener.com
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - Moomoo
ATyr Pharma Fiscal Q2 Loss Narrows - marketscreener.com
aTyr Pharma cuts 60% of workforce after Q2 results - Quiver Quantitative
Atyr Pharma: Q2 Earnings Snapshot - Barchart.com
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
aTyr Pharma Q2 net loss narrows - TradingView
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD - TradingView
aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary - TradingView
aTyr Pharma Prioritizes Efzofitimod Program, Cuts Workforce 60% as FDA Feedback on Phase 3 Sarcoidosis Study Protocol Looms - Quiver Quantitative
ATyr Pharma, Inc. Announces CFO Changes - marketscreener.com
FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership - Stock Titan
ATYR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390 - tradingkey.com
ATYR Stockholders Have Opportunity to Lead aTyr Pharma, Inc. Clas - The National Law Review
Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn - marketscreener.com
BRIEF-aTyr Pharma Q2 Net Income USD 19.531 Million - TradingView
aTyr Pharma Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
ATYR Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares Up 1.19%Earnings Surprise Score - vinanet.vn
aTyr Pharma (ATYR) Rises 1.25% as Shares Defend Key $0.47 Support LevelTrading Ideas - vinanet.vn
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):